SWK Holdings Corp (SWKH) FY2024 10-K Annual Report
SWK Holdings Corp (SWKH) 10-K annual report for fiscal year 2024, filed with SEC EDGAR on Mar 20, 2025. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
SWK Holdings Corp FY2024 10-K Analysis
Business Overview
- • Core business model: dual segments of specialty finance in life sciences and pharmaceutical development/manufacturing
- • Pharmaceutical Development segment entered asset sale process with March 2024 exclusive option to sell Enteris BioPharma assets by January 2026, classified as held for sale as of Dec 31, 2024
- • Focus on sub-$50 million finance transactions niche, with $852.5 million funded across 58 deals since strategy inception, mitigating competition from larger players
- • Finance Receivables fund transactions up to $25 million fully via own capital, syndicating larger deals; no current investment advisory partnerships despite previous collaborations
- • Strategic shift toward potential exit from pharmaceutical manufacturing business, emphasizing finance receivables and asset-light life science capital solutions
Management Discussion & Analysis
- • Revenue $45.0M, up $7.2M YoY; Finance Receivables $4.8M increase, Pharmaceutical Development $2.4M increase
- • Net income $13.5M, down $2.4M YoY; interest expense rose to $4.7M from $1.8M; provision for credit losses increased to $12.8M
- • Best segment: Finance Receivables revenue up $4.8M; worst: $5.8M intangible assets impairment in 2024, goodwill impairment $8.4M in 2023
- • Cash $5.9M, up $1.4M; capital allocation includes $6.0M share repurchases, $64.1M investment funding, $6.2M net credit facility payment
- • Management highlights $277.8M finance receivables portfolio; expects positive 2025 cash flows; risk from floating interest rates and borrower repayments
Risk Factors
- • Regulatory risk: LIBOR transition impacted by the Adjustable Interest Rate (LIBOR) Act of 2022, with synthetic U.S. dollar LIBOR continuing until September 2024
- • Macroeconomic risk: Silicon Valley Bank closure by California Department of Financial Protection and Innovation on March 10, 2023, impacting financial services liquidity
- • Supply chain vulnerability: Life science partner companies face risks from limited suppliers of components and potential manufacturing disruptions
- • Competitive risk: Increasing competition from hedge funds entering royalty and debt-backed investment markets, intensifying pressure on opportunity sourcing
- • Financial risk: Concentration risk due to limited number of significant assets, increasing exposure to individual partner company underperformance or credit losses
SWK Holdings Corp FY2024 Key Financial MetricsXBRL
Revenue
$4M
▲ +200.8% YoY
Net Income
$13M
▼ -15.1% YoY
Operating Margin
320.4%
▼ -89839bp YoY
Net Margin
373.0%
▼ -94870bp YoY
ROE
4.7%
▼ -100bp YoY
Total Assets
$332M
▼ -0.6% YoY
EPS (Diluted)
$1.08
▼ -13.6% YoY
Operating Cash Flow
$23M
▲ +54.8% YoY
Source: XBRL data from SWK Holdings Corp FY2024 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on SWK Holdings Corp
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.